Projections for insulin treatment for diabetics.
The evolution of insulin treatment of diabetes has dramatically changed the natural course of this disease. Modern recombinant DNA technology has brought about many new insulin analogues with improved pharmacokinetics, resulting in better glycemic control. In addition, improved insulin delivery systems, such as insulin pumps and pens, have been introduced to provide convenience and to enhance patient compliance. Efforts are currently being devoted to developing noninvasive insulin formulations, such as oral and pulmonary insulin. A number of products are at different stages of clinical trials. Meanwhile, the quest for a permanent cure for diabetes continues. The frontier of diabetes research has gone through a period of substantial expansion, with the emergence of new areas that include gene therapy, islet cell transplantation and diabetic vaccine. Technological breakthroughs, such as recombinant DNA, nanotechnology, microarray-aided genomics and proteomics, will provide more profound insights into the pathogenesis, and the immunological and biological basis of diabetes. Our growing knowledge in these areas will ultimately contribute to the discovery of preventive methods against or a cure for this disease.
Cao
Ying
Y
Abbott Laboratories, Abbott Park, IL 60064, USA. ying.cao@add.ssw.abbott.com
Lam
Laura
L
D000280:Administration, Inhalation; D000284:Administration, Oral; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D015316:Genetic Therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives / Q000235:genetics / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D016381:Islets of Langerhans Transplantation; D014612:Vaccines / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D014612:Vaccines